Triple threat: new combo therapy aims to tackle rare lung disease
NCT ID NCT07266519
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a triple combination of three drugs—sotatercept, an endothelin receptor antagonist, and a phosphodiesterase-5 inhibitor—can improve blood flow in the lungs of people newly diagnosed with pulmonary arterial hypertension (PAH). The study will enroll 25 treatment-naïve adults and measure changes in pulmonary vascular resistance after 24 weeks. It is an open-label, single-arm study, meaning everyone gets the same treatment and no placebo is used.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sotatercept combined with an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor
What this could lead to
If successful, this triple-drug combination could become a new standard first treatment for pulmonary arterial hypertension, potentially improving blood flow and symptoms better than current options.
What could go wrong
This is a small, early-phase study with only 25 people and no comparison group. Results may not apply to all patients, and side effects from combining three drugs are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••